JP2016523276A - 間質性膀胱炎／膀胱痛症候群（ｉｃ／ｂｐｓ）に関連する疼痛の予防および治療のためのシグマリガンドの使用 - Google Patents

間質性膀胱炎／膀胱痛症候群（ｉｃ／ｂｐｓ）に関連する疼痛の予防および治療のためのシグマリガンドの使用 Download PDF

Info

Publication number
JP2016523276A
JP2016523276A JP2016522457A JP2016522457A JP2016523276A JP 2016523276 A JP2016523276 A JP 2016523276A JP 2016522457 A JP2016522457 A JP 2016522457A JP 2016522457 A JP2016522457 A JP 2016522457A JP 2016523276 A JP2016523276 A JP 2016523276A
Authority
JP
Japan
Prior art keywords
dichlorophenyl
pyrazol
yloxy
substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016522457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523276A5 (enExample
Inventor
ベラ−エルナンデス、ホセ−ミゲル
メルロス−ロカ、マヌエル
バーイエンス−カブレラ、ホセ−マヌエル
センダン−マルティネス、クルス−ミゲル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Esteve Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals SA filed Critical Esteve Pharmaceuticals SA
Publication of JP2016523276A publication Critical patent/JP2016523276A/ja
Publication of JP2016523276A5 publication Critical patent/JP2016523276A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2016522457A 2013-06-26 2014-06-25 間質性膀胱炎／膀胱痛症候群（ｉｃ／ｂｐｓ）に関連する疼痛の予防および治療のためのシグマリガンドの使用 Pending JP2016523276A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382246.0 2013-06-26
EP13382246.0A EP2818166A1 (en) 2013-06-26 2013-06-26 Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
PCT/EP2014/063360 WO2014207024A1 (en) 2013-06-26 2014-06-25 Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps)

Publications (2)

Publication Number Publication Date
JP2016523276A true JP2016523276A (ja) 2016-08-08
JP2016523276A5 JP2016523276A5 (enExample) 2017-08-03

Family

ID=48700506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016522457A Pending JP2016523276A (ja) 2013-06-26 2014-06-25 間質性膀胱炎／膀胱痛症候群（ｉｃ／ｂｐｓ）に関連する疼痛の予防および治療のためのシグマリガンドの使用

Country Status (19)

Country Link
US (1) US20160151377A1 (enExample)
EP (2) EP2818166A1 (enExample)
JP (1) JP2016523276A (enExample)
KR (1) KR20160023839A (enExample)
CN (1) CN105377257A (enExample)
AR (1) AR096709A1 (enExample)
AU (1) AU2014301220A1 (enExample)
BR (1) BR112015032343A8 (enExample)
CA (1) CA2916568A1 (enExample)
HK (1) HK1221656A1 (enExample)
IL (1) IL243362A0 (enExample)
MA (1) MA38711A1 (enExample)
MX (1) MX2015017761A (enExample)
PH (1) PH12015502815A1 (enExample)
RU (1) RU2016102149A (enExample)
SG (1) SG11201510408XA (enExample)
TN (1) TN2015000558A1 (enExample)
TW (1) TWI629984B (enExample)
WO (1) WO2014207024A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
JP2017503765A (ja) * 2013-12-17 2017-02-02 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ガバペンチノイドおよびシグマ受容体の組み合わせ
AU2014364647A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Sigma receptor ligands combinations
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
KR20250116520A (ko) 2024-01-25 2025-08-01 가톨릭대학교 산학협력단 칸나비디올을 유효성분으로 포함하는 방광 통증 증후군의 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006019A1 (fr) * 2001-07-10 2003-01-23 Yamanouchi Pharmaceutical Co., Ltd. Composition medicinale destinee au traitement de la cystite interstitielle
WO2006051797A1 (ja) * 2004-11-10 2006-05-18 Kissei Pharmaceutical Co., Ltd. 間質性膀胱炎の治療薬
JP2013518859A (ja) * 2010-02-04 2013-05-23 ラボラトリオス・デル・ドクター・エステベ・ソシエテ・アノニム 術後疼痛におけるオピオイドおよびオピエートの鎮痛促進効果およびその依存性の予防のためのシグマリガンド

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1781618T3 (pl) 2004-08-27 2013-03-29 Esteve Labor Dr Inhibitory receptora sigma
US20090325975A1 (en) * 2005-07-15 2009-12-31 Helmut H Buschmann Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
MX2008011016A (es) * 2006-03-01 2008-09-08 Esteve Labor Dr Inhibidores de receptor sigma.
CN101395157A (zh) * 2006-03-01 2009-03-25 伊斯特芬博士实验室有限公司 作为西格玛受体抑制剂的吡唑衍生物
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP2353598A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2460804A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del Dr. Esteve, S.A. 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics
EP2460519A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain
UA114711C2 (uk) * 2011-05-13 2017-07-25 Еррей Біофарма Інк. Сполуки піролідинілсечовини й піролідинілтіосечовини як інгібітори кінази trka
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006019A1 (fr) * 2001-07-10 2003-01-23 Yamanouchi Pharmaceutical Co., Ltd. Composition medicinale destinee au traitement de la cystite interstitielle
WO2006051797A1 (ja) * 2004-11-10 2006-05-18 Kissei Pharmaceutical Co., Ltd. 間質性膀胱炎の治療薬
JP2013518859A (ja) * 2010-02-04 2013-05-23 ラボラトリオス・デル・ドクター・エステベ・ソシエテ・アノニム 術後疼痛におけるオピオイドおよびオピエートの鎮痛促進効果およびその依存性の予防のためのシグマリガンド

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIFE SCIENCES, vol. 69, JPN6018007624, 2001, pages 1691 - 1697, ISSN: 0004085170 *
PAIN, vol. 143, JPN6018007622, 2009, pages 252 - 261, ISSN: 0004085169 *

Also Published As

Publication number Publication date
US20160151377A1 (en) 2016-06-02
BR112015032343A8 (pt) 2018-01-23
AU2014301220A1 (en) 2016-02-18
TWI629984B (zh) 2018-07-21
CA2916568A1 (en) 2014-12-31
KR20160023839A (ko) 2016-03-03
RU2016102149A (ru) 2017-08-02
MA38711A1 (fr) 2017-12-29
EP3013338A1 (en) 2016-05-04
CN105377257A (zh) 2016-03-02
MX2015017761A (es) 2016-07-06
IL243362A0 (en) 2016-02-29
WO2014207024A1 (en) 2014-12-31
PH12015502815A1 (en) 2016-03-21
SG11201510408XA (en) 2016-01-28
HK1221656A1 (zh) 2017-06-09
AR096709A1 (es) 2016-01-27
EP2818166A1 (en) 2014-12-31
RU2016102149A3 (enExample) 2018-05-25
TW201536295A (zh) 2015-10-01
BR112015032343A2 (pt) 2017-09-26
TN2015000558A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
JP2016523276A (ja) 間質性膀胱炎／膀胱痛症候群（ｉｃ／ｂｐｓ）に関連する疼痛の予防および治療のためのシグマリガンドの使用
TWI585083B (zh) 用於預防及／或治療手術後疼痛的σ配子
TWI511730B (zh) σ配位體在類鴉片引發之痛覺過敏上的用途
JP6027014B2 (ja) 骨癌の疼痛におけるシグマリガンドの使用
US9789117B2 (en) Use of sigma ligands in diabetes type-2 associated pain
US20160220574A1 (en) Nsaid and sigma receptor ligand combinations
CN105873580B (zh) 加巴喷丁类化合物与σ受体配体的组合物
JP2016516792A (ja) α−２アドレノレセプターおよびシグマレセプターリガンドの組み合わせ物
JP2016540771A (ja) セロトニン−ノルアドレナリン再取り込み阻害薬（ｓｎｒｉ）およびシグマ受容体リガンドの組み合わせ
TW201532605A (zh) α－２腎上腺素受體及σ受體配體組合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190730